Format
Sort by
Items per page

Send to

Choose Destination

Best matches for analgesics, opioid AND opioids AND safety AND united states food and drug administration:

Zohydro approval by food and drug administration: controversial or frightening? Manchikanti L et al. Pain Physician. (2014)

Painful decision-making at FDA. Nelson LS et al. Expert Opin Drug Saf. (2014)

Recent developments toward the safer use of opioids, with a focus on hydrocodone. Covvey JR et al. Res Social Adm Pharm. (2015)

Search results

Items: 1 to 20 of 65

1.

Fibromyalgia: Treating Pain in the Juvenile Patient.

Gmuca S, Sherry DD.

Paediatr Drugs. 2017 Aug;19(4):325-338. doi: 10.1007/s40272-017-0233-5. Review.

PMID:
28536810
2.

Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain.

Behar E, Rowe C, Santos GM, Coffa D, Turner C, Santos NC, Coffin PO.

J Gen Intern Med. 2017 Mar;32(3):291-295. doi: 10.1007/s11606-016-3911-z. Epub 2016 Nov 4.

PMID:
27815762
3.

Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers.

Barber C, Gagnon D, Fonda J, Cho K, Hermos J, Miller M.

Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):40-46. doi: 10.1002/pds.4066. Epub 2016 Aug 16.

PMID:
27530106
4.

ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.

Cepeda MS, Coplan PM, Kopper NW, Maziere JY, Wedin GP, Wallace LE.

Pain Med. 2017 Jan 1;18(1):78-85. doi: 10.1093/pm/pnw129.

5.

Patient safety and the limits of volunteerism.

Goozner M.

Mod Healthc. 2016 Mar 21;46(12):24. No abstract available.

PMID:
27333644
6.

Preparing a prescription drug monitoring program data set for research purposes.

O'Kane N, Hallvik SE, Marino M, Van Otterloo J, Hildebran C, Leichtling G, Deyo RA.

Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):993-7. doi: 10.1002/pds.4039. Epub 2016 Jun 6.

7.

Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J.

J Clin Pharmacol. 2016 Oct;56(10):1243-53. doi: 10.1002/jcph.759. Epub 2016 Jun 10.

PMID:
27145977
8.

Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.

Holder RM, Rhee D.

Pharmacotherapy. 2016 Mar;36(3):287-99. doi: 10.1002/phar.1711. Epub 2016 Mar 6. Review.

PMID:
26945548
9.

Actiq Is Not for Sore Throats!

Shastay A.

Home Healthc Now. 2016 Mar;34(3):158-9. doi: 10.1097/NHH.0000000000000354. No abstract available.

PMID:
26925943
10.

Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.

Seoane-Vazquez E, Rodriguez-Monguio R, Hansen R.

Clin Drug Investig. 2016 Apr;36(4):281-92. doi: 10.1007/s40261-015-0374-7.

PMID:
26818406
11.

Treating Opioid-Induced Constipation in Older Adults: New Options.

Sani H, Mahan RJ.

Consult Pharm. 2015 Oct;30(10):612-5. doi: 10.4140/TCP.n.2015.612.

PMID:
26450143
12.

Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.

Gunderson EW, Hjelmström P, Sumner M; 006 Study Investigators.

Clin Ther. 2015 Oct 1;37(10):2244-55. doi: 10.1016/j.clinthera.2015.08.025. Epub 2015 Sep 26.

13.

Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.

Kao DP, Haigney MC, Mehler PS, Krantz MJ.

Addiction. 2015 Sep;110(9):1468-75. doi: 10.1111/add.13013.

14.

Abuse liability assessment of hydrocodone under current draft regulatory guidelines.

Gauvin DV, McComb M, Code R, Dalton JA, Baird TJ.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:118-29. doi: 10.1016/j.vascn.2015.05.003. Epub 2015 May 9.

PMID:
25969422
15.

Recent developments toward the safer use of opioids, with a focus on hydrocodone.

Covvey JR.

Res Social Adm Pharm. 2015 Nov-Dec;11(6):901-8. doi: 10.1016/j.sapharm.2015.02.001. Epub 2015 Feb 13.

PMID:
25769501
16.

FDA/DEA/PDMP/UDT: alphabet soup or sensible and integrated risk management?

Passik SD, Kirsh KL, Twillman RK.

J Opioid Manag. 2015 Jan-Feb;11(1):77-81. doi: 10.5055/jom.2015.0255.

PMID:
25750168
17.

Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.

Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, Winkel G, Sinha R, Jutras-Aswad D, Huestis MA, Hurd YL.

J Addict Med. 2015 May-Jun;9(3):204-10. doi: 10.1097/ADM.0000000000000118.

18.

Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.

Connery HS.

Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75. doi: 10.1097/HRP.0000000000000075. Review.

PMID:
25747920
19.

Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?

Brooks MJ.

Mayo Clin Proc. 2014 Dec;89(12):1673-84. doi: 10.1016/j.mayocp.2014.09.003. Epub 2014 Nov 4.

20.

Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.

Gould HJ 3rd, Paul D.

Pharmacol Res. 2015 Jan;91:99-103. doi: 10.1016/j.phrs.2014.09.006. Epub 2014 Oct 6. Review.

PMID:
25301538

Supplemental Content

Loading ...
Support Center